Anticoagulants Market by Route of Administration, Anticoagulant Drug, Drug Class, Application

KEY MARKET STATISTICS
Base Year [2023]	USD 40.20 billion
Estimated Year [2024]	USD 44.24 billion
Forecast Year [2030]	USD 79.07 billion
CAGR (%)	10.14%

The FPNV Positioning Matrix is pivotal in evaluating the Anticoagulants Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Anticoagulants Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Anticoagulants Market, highlighting leading vendors and their innovative profiles. These include Akebia Therapeutics, Inc., Aspen Pharmacare Holdings Limited, AstraZeneca PLC, Athenex, Inc., Bayer AG, C.H. Boehringer Sohn AG & Ko. KG, Eisai Co., Ltd., Eli Lilly and Company, Johnson & Johnson, LEO Pharma A/S, Novartis AG, Pfizer Inc., Sanofi S.A., Shenzhen Hepalink Pharmaceutical Group Co., Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Anticoagulants Market to forecast the revenues and analyze trends in each of the following sub-markets:

Route of Administration
- Injectable Anticoagulants
- Oral Anticoagulants
Anticoagulant Drug
- Betrixaban
- Dabigatran
- Edoxaban or Rivaroxaban
- Eliquis
Drug Class
- DTIs
- Factor XA Inhibitors
- Heparin
- Vitamin K Antagonists
Application
- Atrial fibrillation & Heart Attack
- Deep Vein Thrombosis
- Pulmonary Embolism
- Stroke
Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Anticoagulants Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Anticoagulants Market?

3. What are the technology trends and regulatory frameworks in the Anticoagulants Market?

4. What is the market share of the leading vendors in the Anticoagulants Market?

5. Which modes and strategic moves are suitable for entering the Anticoagulants Market?

Product Code: MRR-4358BACA80C2

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Anticoagulants Market, by Region

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increasing prevalence of venous thromboembolism and cardiovascular disorders
  - 5.1.1.2. Rising number of anticoagulation stewardship programs
  - 5.1.1.3. Increasing acceptance of novel oral anticoagulants
- 5.1.2. Restraints
  - 5.1.2.1. Stringent regulations related to drug dosage and clinical approvals
- 5.1.3. Opportunities
  - 5.1.3.1. Introduction of novel anticoagulation therapeutics and increasing R&D investments
  - 5.1.3.2. Use of AI and ML to predict anticoagulation control
- 5.1.4. Challenges
  - 5.1.4.1. Side-effects and complications associated with the usage of oral anticoagulants
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Anticoagulants Market, by Route of Administration

6.1. Introduction
6.2. Injectable Anticoagulants
6.3. Oral Anticoagulants

7. Anticoagulants Market, by Anticoagulant Drug

7.1. Introduction
7.2. Betrixaban
7.3. Dabigatran
7.4. Edoxaban or Rivaroxaban
7.5. Eliquis

8. Anticoagulants Market, by Drug Class

8.1. Introduction
8.2. DTIs
8.3. Factor XA Inhibitors
8.4. Heparin
8.5. Vitamin K Antagonists

9. Anticoagulants Market, by Application

9.1. Introduction
9.2. Atrial fibrillation & Heart Attack
9.3. Deep Vein Thrombosis
9.4. Pulmonary Embolism
9.5. Stroke

10. Americas Anticoagulants Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Anticoagulants Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Anticoagulants Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player

14. Competitive Portfolio

14.1. Key Company Profiles
- 14.1.1. Akebia Therapeutics, Inc.
- 14.1.2. Aspen Pharmacare Holdings Limited
- 14.1.3. AstraZeneca PLC
- 14.1.4. Athenex, Inc.
- 14.1.5. Bayer AG
- 14.1.6. C.H. Boehringer Sohn AG & Ko. KG
- 14.1.7. Eisai Co., Ltd.
- 14.1.8. Eli Lilly and Company
- 14.1.9. Johnson & Johnson
- 14.1.10. LEO Pharma A/S
- 14.1.11. Novartis AG
- 14.1.12. Pfizer Inc.
- 14.1.13. Sanofi S.A.
- 14.1.14. Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
- 14.1.15. Teva Pharmaceutical Industries Ltd.
- 14.1.16. Viatris Inc.
14.2. Key Product Portfolio

15. Appendix

15.1. Discussion Guide
15.2. License & Pricing